Labgenomics Co

Labgenomics Co Equity Growth

The Year-over-Year Equity Growth of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -30.83 %. In the previous year, Year-over-Year Equity Growth was -5.04 % — a change of 511.71% (lower).

Equity Growth

-30.83 %

YoY

511.71%

Last updated:

Year-over-Year Equity Growth of Labgenomics Co is 2025 -30.83 % . Year-over-Year Equity Growth of Labgenomics Co was 2024 -5.04 % . It decreases by 511.71% lower compared to the previous year.

The Labgenomics Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
34.70 KRW
Jan 1, 2019
1.05 KRW
Jan 1, 2020
168.08 KRW
Jan 1, 2021
93.41 KRW
Jan 1, 2022
32.73 KRW
Jan 1, 2023
8.82 KRW
Jan 1, 2024
-5.04 KRW
Jan 1, 2025
-30.83 KRW
The Labgenomics Co Equity Growth history
YEAREquity GrowthYoY
-30.83 %+511.71%
-5.04 %-157.14%
8.82 %-73.05%
32.73 %-64.97%
93.41 %-44.42%
168.08 %+15,945.52%
1.05 %-96.98%
34.70 %-422.81%
-10.75 %-182.41%
13.04 %+202.98%
4.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Year-over-Year Equity Growth of Labgenomics Co is -30.83 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Labgenomics Co

All Key Metrics — Labgenomics Co